From Novartis on April 20, 2023
- The ALITHIOS open-label extension study demonstrated that continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) was associated with reduced risk of disability progression versus those who switched later from teriflunomide to Kesimpta.
- Outcomes related to both disability progression and brain volume change up to five years favored earlier initiation of Kesimpta in people living with RMS.
- A separate ALITHIOS analysis showed consistent safety profile of Kesimpta treatment for up to five years in people with RMS and in . . .
This content is for paid subscribers.Today’s Highlights April 20, 2023